Analysis of the factors related to mortality in patients with bronchiectasis
- PMID: 17374480
- DOI: 10.1016/j.rmed.2007.02.002
Analysis of the factors related to mortality in patients with bronchiectasis
Abstract
Background: Bronchiectasis is a common disabling but rarely fatal disease. However the long-term prognosis and risk factors for mortality are not well known.
Objective: The aim of this study was to determine prospectively the survival and predictive factors of mortality in patients with bronchiectasis, during 4-year follow-up.
Patients and methods: From September 2000 to January 2005 survival of bronchiectasis (as evaluated by computed tomography) and predictors of mortality were assessed in 98 outpatients. Fifty-one of the patients had self-reported history of pulmonary infection including tuberculosis. Baseline data, reevaluated in every single year according to scheduled visits.
Results: The mean age was 61+/-10 and 74% of the patients were female. In total, 16 patients (16.3%) died; mean survival time was 44.06+/-1.6 months. The survival rates were 97%, 89%, 76%, 58% at 1, 2, 3 and 4 years, respectively. Cox proportional hazard model revealed that long-term mortality was significantly associated with age, body mass index (BMI), Medical Research Council (MRC) dyspnea scale, vaccination, radiographic extent, hypoxemia, hypercapnia and functional parameters. However, MRC and BMI had more significant effects on the mortality than the functional parameters.
Conclusions: These results suggest that high BMI, regular vaccination and scheduled visits may have beneficial effects on the survival of bronchiectasis. Besides, presence of hypoxemia, hypercapnia, dyspnea level and radiographic extent were more closely correlated with mortality.
Similar articles
-
Emphysema is an independent risk factor for 5-year mortality in patients with bronchiectasis.Clin Respir J. 2017 Nov;11(6):887-894. doi: 10.1111/crj.12432. Epub 2016 Jan 11. Clin Respir J. 2017. PMID: 26662880
-
Association of body mass index with disease severity and prognosis in patients with non-cystic fibrosis bronchiectasis.Braz J Med Biol Res. 2015 Aug;48(8):715-24. doi: 10.1590/1414-431X20154135. Epub 2015 Jul 10. Braz J Med Biol Res. 2015. PMID: 26176309 Free PMC article.
-
Factors associated with pulmonary hypertension and long-term survival in bronchiectasis subjects.Respir Med. 2016 Oct;119:109-114. doi: 10.1016/j.rmed.2016.08.027. Epub 2016 Aug 30. Respir Med. 2016. PMID: 27692130 Review.
-
Dissociation of lung function, dyspnea ratings and pulmonary extension in bronchiectasis.Respir Med. 2007 Nov;101(11):2248-53. doi: 10.1016/j.rmed.2007.06.028. Epub 2007 Aug 14. Respir Med. 2007. PMID: 17698334
-
Bronchiectasis: new findings in the pathogenesis and treatment of this disease.Curr Opin Infect Dis. 2008 Apr;21(2):163-7. doi: 10.1097/QCO.0b013e3282f4f237. Curr Opin Infect Dis. 2008. PMID: 18317040 Review.
Cited by
-
Prognostic Factors in Adult Patients with Non-Cystic Fibrosis Bronchiectasis.Lung. 2018 Dec;196(6):691-697. doi: 10.1007/s00408-018-0165-z. Epub 2018 Sep 25. Lung. 2018. PMID: 30255201
-
Clinical impact of cardiovascular disease on patients with bronchiectasis.BMC Pulm Med. 2020 Apr 23;20(1):101. doi: 10.1186/s12890-020-1137-7. BMC Pulm Med. 2020. PMID: 32326931 Free PMC article.
-
Bronchiectasis in Türkiye: Data from a Multicenter Registry (Turkish Adult Bronchiectasis Database).Balkan Med J. 2024 May 3;41(3):206-212. doi: 10.4274/balkanmedj.galenos.2024.2023-12-57. Balkan Med J. 2024. PMID: 38700365 Free PMC article.
-
Managing Bronchiectasis: 13 Years of Experience from Sputum to Lung Transplantation.Turk Thorac J. 2020 Jul;21(4):261-265. doi: 10.5152/TurkThoracJ.2019.19040. Turk Thorac J. 2020. PMID: 32687787 Free PMC article.
-
Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis.Respir Res. 2019 Dec 3;20(1):271. doi: 10.1186/s12931-019-1243-3. Respir Res. 2019. PMID: 31796019 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical